Thursday, March 1, 2012

Afrezza blog Sitemap

 
This may not have all the articles in the blog. Please use search in top right section.


Product - Afrezza

  1. All about Technosphere technology
  2. Al Mann's comment on prandial insulin's effect on A1C
  3. Three articles that validate the importance of Afrezza
  4. A review of Lancet article TI+Basal Vs Biaspart insulin in Type 2
  5. Why Afrezza will win over Humalog & Novolog?
  6. How can Afrezza help to reverse the progression of Diabetes in Type 2 patients
  7. Mannkind's claims regarding Afrezza
  8. Afrezza Vs Exubera: Exhaustive comparison
  9. Gen2 inhaler: newer, cheaper, more efficient and better
  10. Inhaled insulin & long term lung function
  11. ADA 2009
  12. Inhaled insulin compared with Aspart
  13. Role of TI at cellular level
  14. Abstracts 1
  15. Why is Afrezza better
  16. Heinemann - comments on TI
  17. Validation of Mannkind's claims regarding Afrezza
  18. Beating a dead horse; failure of Exubera
  19. Basic control theory

Mannkind corp

  1. Mannkind Official website
  2. A guide for newbies
  3. The fate of Mankind
  4. Seeking Alpha Mannkind Transcripts
  5. Mannkind media room
  6. Mannkind's Q&A about Afrezza
  7. Must reads & interviews
  8. Merrill Lynch Mannkind presentation - May 12-2010
  9. Resubmission, Production & Partnership
  10. Transcript of Morgan Stanley Global Healthcare Conference – Sep 13th 2010
  11. The shakedown; my two cents

CEO Alfred Mann

  1. Interview with Alfred E. Mann - June-2010
  2. Know about Founder & CEO of Mannkind: Al Mann
  3. Kudos to Al Mann for a well deserved award
  4. Visionaries and skeptics

Stock – MNKD

  1. Valuation of Mannkind corp
  2. Rebuttal to Oppenheimer comments
  3. Getting philosophical about shorts
  4. Shorts, Bashers & Retarded chimpanzees
  5. BOSPENC's 4 part
  6. The case for Mannkind
  7. Porter five forces analysis for Afrezza – part 1

Trial participants

  1. Feedback from Afrezza Trial participant part 1

  2. Feedback from Afrezza trial participant – part 2

Physicians

  1. A physician’s perspective – June 15, 2010
  2. Interview with Diabetologists regarding Afrezza

Sell side Analysts

  1. Bank of America
  2. Rodman & Renshaw
  3. Wells Fargo
  4. Oppenheimer
  5. JP Morgan
  6. CRT
  7. Hapoalim
  8. Baird
  9. Griffin
  10. Leerink Swann

FDA

  1. FDA's CRL and the possible next steps
  2. A look at FDA guidelines for Afrezza’s approval
  3. Behind FDA's thinking on new guidelines for diabetes drugs

Other Interviews


  1. Fox news video on inhaled insulin
  2. Pete Richardson - Clip syndicate video
  3. Interview with Dr Andrea Leone Bay
  4. Hakan interview - may 26-2010

For patients

  1. Beyond HA1c, Dr Hirsch article
  2. What should people with Diabetes expect from Afrezza?
  3. Afrezza meets the unmet medical need of diabetics
  4. Afrezza and HbA1C part 1
  5. Afrezza and HbA1c part 2
  6. Value of early intervention
  7. Killing two birds with one Inhaler
  8. Rationale for Pulmonary Route
  9. Starting insulin early

Miscellaneous


  1. How to devastate humanity and bankrupt the world
  2. Feedback from real Exubera users